

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number

WO 2021/159027 A9

(43) International Publication Date
12 August 2021 (12.08.2021)

(51) International Patent Classification:

A61K 38/21 (2006.01) A61P 31/14 (2006.01)
A61K 39/215 (2006.01) C07K 14/165 (2006.01)
A61P 11/00 (2006.01)

Inc., 2155 Park Boulevard, Palo Alto, California 94306 (US). **HISLOP, Colin**; c/o Eiger Biopharmaceuticals, Inc., 2155 Park Boulevard, Palo Alto, California 94306 (US).

(21) International Application Number:

PCT/US2021/016963

(74) Agent: **MOUSSA, Akkad Y.** et al.; KILPATRICK TOWNSEND & STOCKTON LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, Suite 2800, Atlanta, Georgia 30309 (US).

(22) International Filing Date:

05 February 2021 (05.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/971,194	06 February 2020 (06.02.2020)	US
63/017,614	29 April 2020 (29.04.2020)	US
63/021,552	07 May 2020 (07.05.2020)	US
63/091,881	14 October 2020 (14.10.2020)	US
63/093,334	19 October 2020 (19.10.2020)	US

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(71) Applicant: **EIGER BIOPHARMACEUTICALS, INC.** [US/US]; 2155 Park Boulevard, Palo Alto, California 94306 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(72) Inventors: **GLENN, Jeffrey**; c/o Eiger Biopharmaceuticals, Inc., 2155 Park Boulevard, Palo Alto, California 94306 (US). **CHOONG, Ingrid**; c/o Eiger Biopharmaceuticals,

(54) Title: TREATMENT OF CORONAVIRUS INFECTION WITH INTERFERON LAMBDA

Eiger peg-IFN Lambda in HAE with SARS-CoV-2




FIG. 1

(57) Abstract: Methods of treating a coronavirus infection in a human subject are provided. In some embodiments, the method comprises subcutaneously administering to the subject a therapeutically effective amount of pegylated interferon lambda-1a.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

22 September 2022 (22.09.2022)

(15) Information about Correction:

see Notice of 22 September 2022 (22.09.2022)